Glimepiride-induced hypoglycemia with ciprofloxacin, metronidazole, and acute kidney injury

Hospital Pharmacy

Volumn 45, Issue 12, 2010, Pages 934-938

  Covvey, Jordan ^a   Lewis, Daniel ^b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

ciprofloxacin; CYP 2C9; glimepiride; hypoglycemia; metronidazole; octreotide; renal insufficiency

Indexed keywords

CARBON DIOXIDE; CHLORIDE; CIPROFLOXACIN; CREATININE; CYTOCHROME P450 2C9; GLIMEPIRIDE; GLUCAGON; GLUCOSE; INSULIN GLARGINE; METRONIDAZOLE; OCTREOTIDE; PIPERACILLIN PLUS TAZOBACTAM; POTASSIUM; SODIUM;

ACUTE KIDNEY FAILURE; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD GLUCOSE MONITORING; CASE REPORT; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIVERTICULITIS; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTHYROIDISM; KIDNEY INJURY; LETHARGY; MALE; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; SALVAGE THERAPY; UREA NITROGEN BLOOD LEVEL; VITAL SIGN;

EID: 78650155417     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4512-934     Document Type: Article

References (40)

1. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care. 2003 Jun;26(6):1852-1855.
2. van Staa T, Abenhaim L, Monette J. Rates of hypoglyce-mia in users of sulfonylureas. J Clin Epidemiol. 1997;50(6): 735-741.
3. Garber SM, Pound MW, Miller SM. Hypoglycemia associated with the use of levofloxacin. Am J Health Syst Pharm. 2009;66(11):1014-1019.
4. Kesavadev J, Rasheed SA. Gatifloxacin induced abnormalities in glucose homeostasis in a patient on glimepiride. J Assoc Physicians India. 2006;54:951-952.
5. Mohr JF, McKinnon PS, Peymann PJ, et al. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy. 2005;25(10):1303-1309.
6. Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Tox-icol. 2004;42(3):295-297.
7. LeBlanc M, Bélanger C, Cossette P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy. Pharmacotherapy. 2004;24(7):926-931.
8. Roberge RJ, Kaplan R, Frank R, et al. Glyburide-cipro-floxacin interaction with resistant hypoglycemia. Ann Emerg Med. 2000;36(2):160-163.
9. Bussing R, Gende A. Severe hypoglycemia from clari-thromycin-sulfonylurea drug interaction. Diabetes Care. 2002; 25(9):1659-16561.
10. Kihara Y, Otsuki M. Interaction of gliclazide and rifam-picin. Diabetes Care. 2000;23(8):1204-1205.
11. Strevel EL, Kuper A, Gold WL. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet Infect Dis. 2006;6(3):178-182.
12. Hekimsoy Z, Biberoglu S, Cömlekxci A, et al. Tri-methoprim/ sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection. Eur J Endocrinol. 1997;136(3):304-306.
13. Johnson JA, Kappel JE, Sharif MN. Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient [review]. Ann Pharmacother. 1993; 27(3):304-306.
14. Johnson JF, Dobmeier ME. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. DICP Ann Pharmacother. 1990;24(3):250-251.
15. Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30(2):389-394.
16. Harrower AD: Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf. 2000;22(4):313-320.
17. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother. 1998;32(10):1044-1052.
18. Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs. 1998; 55(4):563-584.
19. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17(6):467-473.
20. Negishi M, Shimomura K, Proks P, et al. Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009;26(1):76-78.
21. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
22. Frothingham R. Gatifloxacin associated with a 56-fold higher rate of glucose homeostasis abnormalities than comparator quinolones in the FDA spontaneous reporting database. In: Programs and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30 to November 2, 2004; Washington, DC. Abstract A-1092.
23. Aspinall SL, Good CB, Jiang R, et al. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis. 2009; 49(3):402-408.
24. LaPlante KL, Mersfelder TL, Ward KE, et al. Prevalence of and risk factors for dysglycemia in patients receiving gati-floxacin and levofloxacin in an outpatient setting. Pharmaco-therapy. 2008;28(1):82-89.
25. Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy. 2005;25(10):1296-1302.
26. Owens RC Jr. Fluoroquinolone-associated dysglycemias: a tale of two toxicities. Pharmacotherapy. 2005;25(10):1291-1295.
27. Rosenkranz B, Profozic V, Metelko Z, et al. Pharmacoki-netics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996; 39(12):1617-1624.
28. Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res. 1996;28(9):434-9.
29. Amaryl (glimepiride). Product information. Bridgewater, NJ: sanofi-aventis; revised. July 2009.
30. Lomaestro BM. Fluoroquinolone-induced renal failure. Drug Saf. 2000;22:479-485.
31. Stahlmann R, Lode H. Safety considerations of fluo-roquinolones in the elderly: an update. Drugs Aging. 2010; 27(3):193-209.
32. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med. 1976;295(7):354-357.
33. Blyden GT, Scavone JM, Greenblatt DJ. Metronidazole impairs clearance of phenytoin but not of alprazolam or lor-azepam. J Clin Pharmacol. 1988;28(3):240-245.
34. Niemi M, Backman JT, Neuvonen M, et al. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther. 2001;69(4):194-200.
35. Niemi M, Neuvonen PJ, Kivistö KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glime-piride. Clin Pharmacol Ther. 2001;70(5):439-445.
36. Niemi M, Kivistö KT, Backman JT, et al. Effect of rifam-picin on the pharmacokinetics and pharmacodynamics of gli-mepiride. Br J Clin Pharmacol. 2000;50(6):591-595.
37. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6(4):341-349.
38. Niemi M, Cascorbi I, Timm R, et al. Glyburide and gli-mepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002;72(3):326-332.
39. Ragia G, Petridis I, Tavridou A, et al. Presence of CYP2C9p3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacoge-nomics. 2009;10(11):1781-1787.
40. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007; 41(4):674-680. Epub 2007 Mar 27.